Associated Papers
Gene editing for collagen disorders: current advances and future perspectives.
Kocsy K et al.
Gene Therapy, 2025
Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa.
Hunt JMT et al.
Molecular Therapy. Nucleic Acids, 2025
Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C et al.
The Journal of Investigative Dermatology, 2024
Generation and characterization of induced pluripotent stem cell lines from two patients with recessive dystrophic epidermolysis Bullosa.
Vincent C et al.
Stem Cell Research, 2023
High-efficiency RNA-based reprogramming of human primary fibroblasts.
Kogut I et al.
Nature Communications, 2018
Revertant mosaicism in genodermatoses.
Lim YH et al.
Cellular and Molecular Life Sciences : Cmls, 2017
Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
Turczynski S et al.
The Journal of Investigative Dermatology, 2016
Natural gene therapy in dystrophic epidermolysis bullosa.
van den Akker PC et al.
Archives of Dermatology, 2012
Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations.
van den Akker PC et al.
Journal of Dermatological Science, 2009
Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
Dang N et al.
Experimental Dermatology, 2008
Expanding the COL7A1 mutation database: novel and recurrent mutations and unusual genotype-phenotype constellations in 41 patients with dystrophic epidermolysis bullosa.
Kern JS et al.
The Journal of Investigative Dermatology, 2006
Select a paper to view details